Ann Kramer CEO of Electrospinning answers our questions
This article is the second in a series where we ask industry experts how they see the competition in their industry. We also ask them what’s their understanding of Competitive Intelligence. This week we hear from Oxford based Ann Kramer CEO of Electrospinning.
1. How is Machine learning / AI affecting your business (- 1–10 low to high)
2. How competitive is your industry?(- 1–10 low to high)
3. Is your industry getting more or less competitive?(- 1–10 low to high)
4. Where do you see your industry in 3 years?
Change from an emerging technology to one that is recognised and being adopted by larger industry players.
5. What is making your industry more/less competitive?
Market growth is attracting more entrants/ cash into scale-up
6. What are the key threats to your industry?
Reputational damage in case the technology does not deliver at scale
7. What are the main opportunities in your industry sector?
Demographics. Ageing populations are wanting to live active lives for longer — without paying a fortune.
8. In your view, what is Competitive Intelligence?
Awareness of competitors, substitutes and market activity.
Who is the Electrospinning Company?
We design, develop and manufacture advanced biomaterials for use in implantable tissue-regenerative devices. The company supplies the first electrospun material to be incorporated into an FDA-approved medical device that promotes endogenous tissue repair in orthopaedic surgery. Our tried and tested processes support our customers from developing electrospun prototypes towards registration with the FDA or notified bodies and long term manufacturing. Our experience in electrospinning, manufacturing and quality management allows us to offer cost-effective production of electrospun medical devices at scale. With over 30 years of combined experience in biomedical electrospinning, we are actively looking to engage with other partners to bring the benefits of electrospun biomaterials to a range of therapeutic indications. The company operates out of Class VII clean rooms and holds ISO 13485:2016 medical device quality certification.
Ann Kramer, CEO
Ann graduated from the University of Cambridge with a degree in Natural Sciences and joined ICI Agrochemicals. Over almost 20 years with ICI, Zeneca and Syngenta, she gained experience across the business, including in research, sales, business development and M&A, with roles in the UK, USA and Switzerland. She managed the development of genetically modified food business streams in fresh produce crops. Since 2006 she has worked in the SME sector in the UK as Head of Business development for Oxitec Ltd. (acquired by Intrexon in 2015), COO of Immunocore Ltd. and CEO of Biosyntha Ltd. She joined The Electrospinning Company as CEO in 2012.
What is Electrospinning?
It’s not a sector you will come across every day. According to Nanoscience.com electrospinning is a voltage-driven process. The process is governed by the electrohydrodynamic phenomena, where fibers and particles are made from a polymer solution. The most basic set-up for this technique involves a solution contained in a reservoir (typically a syringe) and tipped with a blunt needle (for needle-based electrospraying), a pump, a high voltage power source and a collector.
Ann Kramer CEO of Electrospinning answers our questions.
In this article, Ann Kramer CEO of Electrospinning answers our questions. It’s the second in a series where we ask industry experts how they see the competition. If you would like to take part, please let us know at firstname.lastname@example.org